Unite de Fabrication de Medicaments SA (UMED)

Currency in TND
9.30
-0.05(-0.53%)
Closed·
UMED Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
UMED is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.249.35
52 wk Range
6.839.50
Key Statistics
Bid/Ask
9.25 / 9.30
Prev. Close
9.35
Open
9.35
Day's Range
9.24-9.35
52 wk Range
6.83-9.5
Volume
14.32K
Average Volume (3m)
27.19K
1-Year Change
31.88%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
UMED Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.00
Upside
+39.78%
Members' Sentiments
Bearish
Bullish
ProTips
Pays a significant dividend to shareholders

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Unite de Fabrication de Medicaments SA Company Profile

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals. Unité de Fabrication des Médicaments S.A. was founded in 1989 and is based in Sousse, Tunisia.

Employees
572
Market
Tunisia

Compare UMED to Peers and Sector

Metrics to compare
UMED
Peers
Sector
Relationship
P/E Ratio
15.4x−3.1x−0.5x
PEG Ratio
0.060.010.00
Price/Book
2.6x2.0x2.6x
Price / LTM Sales
2.0x1.5x3.3x
Upside (Analyst Target)
39.0%109.5%43.5%
Fair Value Upside
Unlock24.3%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.00
(+39.78% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.61%
Dividend Yield
-
Industry Median 5.13%
Annualised payout
-
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
33.30M / --
EPS Revisions
Last 90 days

UMED Income Statement

People Also Watch

1.970
CC
0.00%
21.80
STPIL
-1.31%
7.18
TLNET
+0.84%
13.20
ECYCL
+0.76%

FAQ

What Stock Exchange Does Unite de Fabrication de Medicaments Trade On?

Unite de Fabrication de Medicaments is listed and trades on the Tunis Stock Exchange stock exchange.

What Is the Stock Symbol for Unite de Fabrication de Medicaments?

The stock symbol for Unite de Fabrication de Medicaments is "UMED."

What Is the Unite de Fabrication de Medicaments Market Cap?

As of today, Unite de Fabrication de Medicaments market cap is 297.60M.

What Is Unite de Fabrication de Medicaments's Earnings Per Share (TTM)?

The Unite de Fabrication de Medicaments EPS (TTM) is 0.61.

When Is the Next Unite de Fabrication de Medicaments Earnings Date?

Unite de Fabrication de Medicaments will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is UMED a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Unite de Fabrication de Medicaments Stock Split?

Unite de Fabrication de Medicaments has split 2 times.

How Many Employees Does Unite de Fabrication de Medicaments Have?

Unite de Fabrication de Medicaments has 572 employees.

What is the current trading status of Unite de Fabrication de Medicaments (UMED)?

As of 07 Aug 2025, Unite de Fabrication de Medicaments (UMED) is trading at a price of 9.30, with a previous close of 9.35. The stock has fluctuated within a day range of 9.24 to 9.35, while its 52-week range spans from 6.83 to 9.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.